Associated Genetic Biomarkers
X-ray repair complementing defective repair in Chinese hamster cells 2 (XRCC2) is a gene that encodes a protein that is involved in maintenance of chromosome stability and DNA damage repair. Missense mutations, silent mutations, frameshift deletions, and frameshift insertions are observed in cancers such as testicular cancer, colon cancer, and stomach cancer.
XRCC2 is altered in 0.62% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, cutaneous melanoma, and prostate adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in XRCC2 are XRCC2 Mutation (0.36%), XRCC2 Amplification (0.10%), XRCC2 Loss (0.05%), XRCC2 R159H (0.02%), and XRCC2 H40R (0.01%) .
XRCC2 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain XRCC2 status as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
Trials with XRCC2 status in the inclusion eligibility criteria most commonly target malignant solid tumor and urothelial carcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are XRCC2 Loss and XRCC2 Mutation .
Olaparib, copanlisib, and durvalumab are the most frequent therapies in trials with XRCC2 as an inclusion criteria .
Significance of XRCC2 in Diseases
Urothelial Carcinoma +
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.